As of June 30, 2025, Aethlon had a cash balance of approximately $3.8M. “In Q1, we advanced our lead oncology program, delivered preclinical results supporting broader applications including Long COVID – all while significantly reducing operating expenses,” said CEO James Frakes. “We remain committed to driving the Hemopurifier toward regulatory approval and unlocking its potential across multiple disease areas.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEMD:
- Aethlon Medical: Hold Rating Amidst Promising Technology and Financial Challenges
- Aethlon Medical assumed with a Neutral at H.C. Wainwright
- Aethlon’s Earnings Call: Clinical Progress Amid Financial Hurdles
- Aethlon Medical Reports Q4 Financial Results and Achievements
- Morning Movers: Li Auto lower following Q2 delivery guidance cut